Free Trial
NASDAQ:SCNI

Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis

Scinai Immunotherapeutics logo
$2.82 +0.05 (+1.81%)
As of 10:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Scinai Immunotherapeutics Stock (NASDAQ:SCNI)

Key Stats

Today's Range
$2.73
$2.82
50-Day Range
$1.92
$3.54
52-Week Range
$1.90
$8.92
Volume
2,620 shs
Average Volume
278,868 shs
Market Capitalization
$2.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Scinai Immunotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

SCNI MarketRank™: 

Scinai Immunotherapeutics scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Scinai Immunotherapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Scinai Immunotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Scinai Immunotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Scinai Immunotherapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.24% of the float of Scinai Immunotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Scinai Immunotherapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Scinai Immunotherapeutics has recently decreased by 57.89%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Scinai Immunotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Scinai Immunotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.24% of the float of Scinai Immunotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Scinai Immunotherapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Scinai Immunotherapeutics has recently decreased by 57.89%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Scinai Immunotherapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Scinai Immunotherapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Scinai Immunotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    60.90% of the stock of Scinai Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    58.41% of the stock of Scinai Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Scinai Immunotherapeutics' insider trading history.
Receive SCNI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scinai Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SCNI Stock News Headlines

Donald Trump is about to free crypto from its chains …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.
Scinai Immunotherapeutics Ltd. (SCNI)
See More Headlines

SCNI Stock Analysis - Frequently Asked Questions

Scinai Immunotherapeutics' stock was trading at $3.35 at the start of the year. Since then, SCNI shares have decreased by 15.6% and is now trading at $2.8260.
View the best growth stocks for 2025 here
.

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) issued its earnings results on Friday, November, 22nd. The company reported $8.40 earnings per share for the quarter.

Scinai Immunotherapeutics's stock reverse split before market open on Tuesday, May 21st 2024. The 1-10 reverse split was announced on Tuesday, May 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of SCNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Scinai Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), AppLovin (APP), e.l.f. Beauty (ELF) and Disc Medicine (IRON).

Company Calendar

Last Earnings
11/22/2024
Today
5/02/2025
Next Earnings (Estimated)
5/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SCNI
Previous Symbol
NASDAQ:SCNI
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,500,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$452,000.00
Price / Cash Flow
N/A
Book Value
($9.84) per share
Price / Book
-0.29

Miscellaneous

Free Float
334,000
Market Cap
$2.64 million
Optionable
Not Optionable
Beta
2.68
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:SCNI) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners